摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[6-chloro-2-methyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazolo[1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-propyl-amine | 444324-75-8

中文名称
——
中文别名
——
英文名称
[6-chloro-2-methyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazolo[1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-propyl-amine
英文别名
[6-Chloro-2-methyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazo[1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-propyl-amine;N-[[6-chloro-2-methyl-7-(2,4,6-trimethylphenyl)imidazo[1,2-a]imidazol-3-yl]methyl]-N-(cyclopropylmethyl)propan-1-amine
[6-chloro-2-methyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazolo[1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-propyl-amine化学式
CAS
444324-75-8
化学式
C23H31ClN4
mdl
——
分子量
398.979
InChiKey
VIOCZKJYKFTMHC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.5
  • 重原子数:
    28
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    25.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    6-Chloro-2-methyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazo[1,2-a]imidazole-3-carboxylic acid cyclopropylmethyl-propyl-amide 在 红铝 作用下, 以 甲苯 为溶剂, 以64%的产率得到[6-chloro-2-methyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazolo[1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-propyl-amine
    参考文献:
    名称:
    Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists
    摘要:
    A novel series of [6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethyl]-dialkylamines was discovered as potent CRF1R antagonists. The optimization of binding affinity in the series by the parallel reaction approach is discussed herein. (c) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.04.094
点击查看最新优质反应信息

文献信息

  • Imidazolyl derivatives as corticotropin releasing factor inhibitors
    申请人:——
    公开号:US20020183375A1
    公开(公告)日:2002-12-05
    The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1 useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    本发明涉及一种新型杂环拮抗剂,其化学式为(I),以及包含所述拮抗剂的药物组合物,用于治疗抑郁症、焦虑症、情感障碍、进食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状以及其他可以通过拮抗CRF-1受体来治疗的病症。
  • US6888004B2
    申请人:——
    公开号:US6888004B2
    公开(公告)日:2005-05-03
  • US7125990B2
    申请人:——
    公开号:US7125990B2
    公开(公告)日:2006-10-24
  • US7211669B2
    申请人:——
    公开号:US7211669B2
    公开(公告)日:2007-05-01
  • US7238699B2
    申请人:——
    公开号:US7238699B2
    公开(公告)日:2007-07-03
查看更多